Asthma is a chronic lung disease characterized by airflow obstruction, bronchial hyper-reactivity and inflammation of the airways. Immunoglobulin E (IgE) plays an important role in the pathogenesis of asthma. Blocking IgE binding to its high affinity FcεR1 with anti-IgE (omalizumab, Xolair®) can provide moderate-to-severe asthma patients with certain levels of clinical benefit by reducing asthma exacerbations, symptoms, and oral corticosteroid doses, as well as improving quality of life.

中文翻译：

---

肥胖影响抗 IgE（奥马珠单抗）治疗哮喘的结果

哮喘是一种慢性肺部疾病，其特征是气流阻塞、支气管高反应性和气道炎症。免疫球蛋白 E (IgE) 在哮喘的发病机制中起重要作用。用抗 IgE（奥马珠单抗、Xolair®）阻断 IgE 与其高亲和力 FcεR1 的结合，可以通过减少哮喘发作、症状和口服皮质类固醇剂量以及提高质量，为中度至重度哮喘患者提供一定程度的临床益处的生活。